Nordmark Pharma
Nordmark Pharma GmbH is a privately held German biopharmaceutical manufacturer specializing in biological and biotechnological APIs (world leader in pancreatin and collagenase), branded products (Pankreatan, Thrombophob), and full-service CDMO services for global biopharma, research, and healthcare customers.
- Company typePrivate
- Founded1930
- HeadquartersUetersen, Germany
- Headcount251–500
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Nordmark Pharma does
Nordmark Pharma GmbH is a privately held German biopharmaceutical manufacturer headquartered in Uetersen, Schleswig-Holstein, with additional process development operations at BIBITEC in Bielefeld. The company specializes in the manufacture of active pharmaceutical ingredients (APIs) and finished drug products of biological and biotechnological origin, and self-describes as worldwide leading in the production of pancreatin and collagenase. Its portfolio spans three integrated business lines: (1) proprietary pharmaceutical products including Pankreatan for pancreatic exocrine insufficiency and Thrombophob 60.000 (heparin-based topical), distributed via pharmacies; (2) a biochemicals portfolio under the Collagenase NB and Neutral Protease NB brands sold globally for in vitro research and clinical cell-isolation use; and (3) a full-service CDMO offering covering microbial fermentation (up to 500 L pilot scale), mammalian cell culture (up to 200 L via BIBITEC), downstream processing, and drug product formulation (orals, topicals, parenterals) under cGMP for Phase I-III clinical and commercial supply.
The company operates at FDA-audited, highest cGMP quality levels and serves four primary customer segments: biopharmaceutical companies seeking CDMO partnerships, healthcare professionals prescribing Pankreatan/Thrombophob, research institutions and clinics purchasing biochemicals, and patients receiving branded products through pharmacies. Its go-to-market combines direct enterprise sales, participation in major industry congresses (EPC, DPC, BIO, CPhI, German Biotech Days), the GastroLive digital training series for gastroenterologists, and dedicated HCP/pharmacy service portals. Ownership is independent and private, led by CEO Dr. Jörn Tonne and four additional managing directors, with Ulf Tonne chairing the supervisory board; the firm employs 501-1000 people and has no disclosed external funding rounds or parent company.
Nordmark Pharma firmographics
Firmographics- Name
- Nordmark Pharma
- Legal name
- Nordmark Pharma GmbH
- Website
- https://nordmark-pharma.de
- Company type
- Private
- Founded year
- 1930
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Nordmark Pharma GmbH is a privately held German biopharmaceutical manufacturer specializing in biological and biotechnological APIs (world leader in pancreatin and collagenase), branded products (Pankreatan, Thrombophob), and full-service CDMO services for global biopharma, research, and healthcare customers.
- Ownership category
- akta.pro rank
Nordmark Pharma industry classification
Industry- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)
- akta.pro secondary industry
- Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)
Keywords
Where Nordmark Pharma is headquartered
LocationHeadquarters
- HQ city
- Uetersen
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Nordmark Pharma business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical Products: Sale of finished pharmaceutical products including Pankreatan (pancreatin) for pancreatic enzyme replacement therapy and Thrombophob (heparin-based cream) for sports injuries and superficial phlebitis. Products sold to patients via pharmacies and to healthcare professionals.
- Biochemicals: Sale of biochemical products including collagenases, neutral proteases, and clostripain for research and clinical applications. These are sold for in vitro use only, for research and laboratory purposes.
- Contract Manufacturing Services: Full service CDMO offering for biopharmaceutical companies - from development, analytical testing, clinical trials, regulatory support, and project management through to GMP manufacturing of drug substances and drug products for clinical supply (Phase I-III).
- Thyroid Extract: Production and sale of desiccated thyroid extract as a pharmaceutical product.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Nordmark Pharma product offering
Product offeringCore offering
Nordmark Pharma is a biopharmaceutical Full Service Provider specializing in the manufacture of active pharmaceutical ingredients and drug products of biological and biotechnological origin. The company offers the complete pharmaceutical value chain as a one-stop-shop—from development, analytical testing, clinical trial supply, regulatory support, and project management through to GMP manufacturing of drug substances and finished drug products. It also sells proprietary finished medications (Pankreatan, Thrombophob) and a comprehensive biochemical enzyme portfolio (Collagenase NB, Neutral Protease, Clostripain) for research and clinical applications.
Product overview
Nordmark Pharma operates as a biopharmaceutical Full Service Provider offering a vertically integrated portfolio combining proprietary pharmaceutical products and contract development and manufacturing (CDMO) services. The pharmaceutical arm includes patient medications Pankreatan (pancreatic enzyme replacement for exocrine insufficiency) and Thrombophob 60.000 (heparin-based topical for injuries and phlebitis), alongside active pharmaceutical ingredients Pancreatin, Collagenase, and Desiccated Thyroid Extract where Nordmark holds global market leadership positions. The biochemicals portfolio features the comprehensive Collagenase NB product line in multiple grades (Premium, Proved, Standard, Sterile, GMP, Gentle, Broad Range) plus Neutral Protease and Clostripain enzymes for research and clinical applications. Through subsidiaries Nordmark Biotech and BIBITEC, the company provides end-to-end CDMO services spanning drug substance manufacturing via microbial fermentation (up to 500L) and mammalian cell culture (up to 200L), through drug product formulation (orals, topicals, parenterals), all under cGMP conditions for clinical trial supply (Phase I-III) and commercial production—positioniting Nordmark as a one-stop-shop covering the complete pharmaceutical value chain from development through regulatory approval and market supply.
Differentiator
Problem solved
Functional benefit
Brands
- Pankreatan: Pharmaceutical product for pancreatic exocrine insufficiency (PEI)
- Thrombophob
- BIBITEC
- Nordmark Biochemicals
- Nordmark Biotech
Companies that use Nordmark Pharma
Customer profileSegments4 records
Ideal customer profiles3 records
Nordmark Pharma technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Nordmark Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BIBITECcoreBIBITEC is a wholly-owned subsidiary of Nordmark conducting mammalian cell culture-based process development and protein production. Located in Bielefeld, Germany, BIBITEC handles upstream development of mammalian cell culture processes from lab scale (<1 L) to pilot scale (up to 200 L) for GMP clinical supply manufacturing.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Nordmark Pharma competitors and assessment
Company assessmentDirect peers
- Celonic Group: German-headquartered CDMO offering mammalian and microbial GMP biomanufacturing plus process development for clinical and commercial supply. Highly comparable technology stack (CHO/microbial) and mid-market European CDMO positioning.
- Siegfried Holding: Swiss CDMO offering API manufacturing including biologics and finished drug products to pharma clients. Comparable vertical integration from API to finished dosage form and European-headquartered mid-market CDMO profile.
- Vibalogics: German-based biologics CDMO with BSL-2 viral and gene therapy capabilities using mammalian and microbial expression systems. Comparable full-service positioning and German regulatory footprint to Nordmark Biotech.
- Rentschler Biopharma: German biopharmaceutical CDMO focused on mammalian cell-culture process development and GMP manufacturing for clinical supply. Closely comparable to Nordmark's BIBITEC unit in scale (pilot-to-Phase III mammalian CDMO) and customer profile (European biotechs).
- Worthington Biochemical: US-based supplier of collagenase, protease, and other enzymes for cell isolation and bioprocessing applications. Directly comparable biochemical product portfolio to Nordmark Biochemicals' Collagenase NB and Neutral Protease lines.
Broad incumbents
- Stada Arzneimittel: German specialty/generic pharmaceutical company selling finished drug products across Europe. Comparable as a German-headquartered branded specialty pharma selling into pharmacies and HCPs, though at significantly larger scale and broader portfolio than Nordmark.
- Catalent Biologics: Global biologics CDMO offering cell-line development, process development, and GMP manufacturing for mammalian-based biotherapeutics. Comparable full-service value proposition but at commercial-scale bioreactor capacities.
- Lonza Biologics: Global leader in mammalian and microbial biologics contract manufacturing across all clinical and commercial scales. Competes with Nordmark for European biopharma CDMO work but at vastly larger capacity (10,000L+ stainless and 2,000L+ single-use).
- Boehringer Ingelheim BioXcellence: Larger German biopharmaceutical CDMO division of Boehringer Ingelheim offering mammalian and microbial contract manufacturing at commercial scale. Overlaps with Nordmark's CDMO offering but operates at materially larger bioreactor scale.
Regional players
- SERVA Electrophoresis: German supplier of biochemicals, enzymes, and life-science research reagents serving European academic and biotech customers. Comparable as a German specialty biochemical products supplier, though broader product scope.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Nordmark Pharma social profiles
Digital presenceNordmark Pharma compliance and trust
Trust signalCompliance2 records
Nordmark Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nordmark Pharma leadership team
Management profileNumber of profiles
Profiles5 records
Nordmark Pharma subsidiaries and ownership
Company hierarchySubsidiaries4 records
Nordmark Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nordmark Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nordmark Pharma
What does Nordmark Pharma do?
Nordmark Pharma is a biopharmaceutical Full Service Provider specializing in the manufacture of active pharmaceutical ingredients and drug products of biological and biotechnological origin. The company offers the complete pharmaceutical value chain as a one-stop-shop—from development, analytical testing, clinical trial supply, regulatory support, and project management through to GMP manufacturing of drug substances and finished drug products. It also sells proprietary finished medications (Pankreatan, Thrombophob) and a comprehensive biochemical enzyme portfolio (Collagenase NB, Neutral Protease, Clostripain) for research and clinical applications.
Is Nordmark Pharma a public or private company?
Nordmark Pharma is a private company. It is currently operating.
When was Nordmark Pharma founded?
Nordmark Pharma was founded in 1930. It employs 251 to 500 people.
Where is Nordmark Pharma based?
Nordmark Pharma is headquartered in Uetersen, Germany, in the Europe region.
How does Nordmark Pharma make money?
Four revenue lines are on record. Pharmaceutical Products are the primary driver. The others are biochemicals, contract Manufacturing Services and thyroid Extract.
Who are Nordmark Pharma's main competitors?
Direct peers on record are Celonic Group, Siegfried Holding, Vibalogics, Rentschler Biopharma and Worthington Biochemical. Broad incumbents are Stada Arzneimittel, Catalent Biologics, Lonza Biologics and Boehringer Ingelheim BioXcellence. SERVA Electrophoresis is listed as a regional player.
Does Nordmark Pharma have an API?
No public API is recorded for Nordmark Pharma.
What industry is Nordmark Pharma in?
Its primary akta.pro industry code is HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ), with a secondary code of HLAIABAG, Generic APIs & Intermediates (Active Ingredients). Its NAICS code is 325414 and its SIC code is 2834.